The Importance of Evaluating Serum Levels of Tumor Markers M2-PK and Inhibin A in Patients Undergoing Colonoscopy
Authors:
Open Access
- 1 January 2023
- journal article
- research article
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 22
Abstract
Despite the use of colonoscopy to detect colon cancer due to its aggressiveness, high cost, and lack of patient compliance, the use of laboratory tests with high accuracy and sensitivity, such as tumor marker M2-PK and Inhibin A is recommended and can be effective for early diagnosis and screening of patients in the early stages. We studied 46 patients admitted it the gastrointestinal ward of Amir al Momenin Hospital and 45 normal (age and sex-matched) subjects as a control group (case-control and retrospective studies). Before the colonoscopy, the level of tumor marker M2-PK in the stool sample and the serum level of Inhibin A were evaluated in patients and the control group. The level of tumor marker M2-PK was significantly higher in the group with hyperplastic polyps and colon cancer ( P < .001) than in the control group. At the same time, there was no significant difference in Inhibin A level ( P = .054). In the hyperplastic polyps group 73% and in the colorectal cancer group 27% had a positive immunochemical fecal occult blood (IFOBT) result, significantly higher than the control group ( P < .001). Evaluation of the level of tumor marker M2-PK in the stool sample in association with the three-time iFOBT test method may be suggested as a quick and noninvasive method for screening and diagnosis of polyps and early stages of colon cancer.Keywords
This publication has 32 references indexed in Scilit:
- Correlation between Faecal Tumour M2 Pyruvate Kinase and Colonoscopy for the Detection of Adenomatous Neoplasia in a Secondary Care CohortJournal of Gastrointestinal and Liver Diseases, 2016
- Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinaseBiochemia Medica, 2016
- The Usefulness of a Novel Screening Kit for Colorectal Cancer Using the Immunochromatographic Fecal Tumor M2 Pyruvate Kinase TestGut and Liver, 2015
- A systematic review and meta-analysis of the diagnostic accuracy of pyruvate kinase M2 isoenzymatic assay in diagnosing colorectal cancerWorld Journal of Surgical Oncology, 2015
- Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screeningWorld Journal of Gastrointestinal Oncology, 2012
- The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growthNature, 2008
- Pyruvate kinase M2 is a phosphotyrosine-binding proteinNature, 2008
- Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancerEuropean Journal of Gastroenterology & Hepatology, 2007
- Tumour M2-pyruvate kinase: a gastrointestinal cancer markerEuropean Journal of Gastroenterology & Hepatology, 2007
- Comparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer.2004